List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8161050/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. European Journal of Preventive Cardiology, 2022, 28, 1795-1806.	1.8	13
2	Impairment of mitophagy and autophagy accompanies calcific aortic valve stenosis favouring cell death and the severity of disease. Cardiovascular Research, 2022, 118, 2548-2559.	3.8	24
3	Phenotypic heterogeneity of COVIDâ€19 pneumonia: clinical and pathophysiological relevance of the vascular phenotype ^a . ESC Heart Failure, 2022, 9, 263-269.	3.1	3
4	The future of cardiovascular prevention: between fiction and reality. European Journal of Preventive Cardiology, 2022, , .	1.8	0
5	OUP accepted manuscript. European Heart Journal Supplements, 2022, 24, B1.	0.1	0
6	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction–Âinsights from the <scp>ESCâ€HFA EORP</scp> Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2022, 24, 335-350.	7.1	49
7	Cardiac Calcifications: Phenotypes, Mechanisms, Clinical and Prognostic Implications. Biology, 2022, 11, 414.	2.8	4
8	Similarities between fibroblasts and cardiomyocytes in the study of the permeability transition pore. European Journal of Clinical Investigation, 2022, 52, e13764.	3.4	2
9	Renin-Angiotensin-Aldosterone System Inhibitors, Statins, and Beta-Blockers in Diabetic Patients With Critical Limb Ischemia and Foot Lesions. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 107424842211019.	2.0	2
10	Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 1162-1170.	7.1	13
11	Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure. Platelets, 2021, 32, 560-567.	2.3	31
12	Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease. European Journal of Preventive Cardiology, 2021, 28, 1460-1466.	1.8	21
13	Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. European Journal of Preventive Cardiology, 2021, 28, 432-445.	1.8	11
14	The New ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes: the Good and the Not So Good. Current Problems in Cardiology, 2021, 46, 100554.	2.4	10
15	Left ventricular output indices in hospitalized heart failure: when "simpler―may not mean "better― International Journal of Cardiovascular Imaging, 2021, 37, 59-68.	1.5	2
16	Diastolic dysfunction, frailty and prognosis in elderly patients with acute coronary syndromes. International Journal of Cardiology, 2021, 327, 31-35.	1.7	6
17	Use of risk scores to identify lower and higher risk subsets among COMPASSâ€eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry. Clinical Cardiology, 2021, 44, 58-65.	1.8	2
18	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 28-33.	4.0	2

#	Article	IF	CITATIONS
19	Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 287-294.	4.0	3
20	Myocarditis in COVID-19 patients: current problems. Internal and Emergency Medicine, 2021, 16, 1123-1129.	2.0	78
21	Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. Critical Care, 2021, 25, 74.	5.8	94
22	Time course of endothelial dysfunction markers and mortality in COVIDâ€19 patients: A pilot study. Clinical and Translational Medicine, 2021, 11, e283.	4.0	41
23	A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients. Cell Reports, 2021, 35, 108983.	6.4	21
24	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp> . European Journal of Heart Failure, 2021, 23, 872-881.	7.1	160
25	Standard ECG in Brugada Syndrome as a Marker of Prognosis: From Risk Stratification to Pathophysiological Insights. Journal of the American Heart Association, 2021, 10, e020767.	3.7	11
26	Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. European Journal of Internal Medicine, 2021, 89, 65-75.	2.2	18
27	Prevalence, Incidence and Prognostic Implications of Left Bundle Branch Block in Patients with Chronic Coronary Syndromes (From the CLARIFY Registry). American Journal of Cardiology, 2021, 150, 40-46.	1.6	3
28	The Combination of Chest Computed Tomography and Standard Electrocardiogram Provides Prognostic Information and Pathophysiological Insights in COVID-19 Pneumonia. Journal of Clinical Medicine, 2021, 10, 3031.	2.4	4
29	Well-Known and Novel Players in Endothelial Dysfunction: Updates on a Notch(ed) Landscape. Biomedicines, 2021, 9, 997.	3.2	15
30	International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. Circulation, 2021, 144, 512-523.	1.6	25
31	Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice. European Journal of Internal Medicine, 2021, 90, 10-15.	2.2	6
32	Adding a "Notch―to Cardiovascular Disease Therapeutics: A MicroRNA-Based Approach. Frontiers in Cell and Developmental Biology, 2021, 9, 695114.	3.7	15
33	Looking for a Tailored Therapy for Heart Failure: Are We Capable of Treating the Patient Instead of the Disease?. Journal of Clinical Medicine, 2021, 10, 4325.	2.4	3
34	â€~Corona' versus â€~coronary'. European Heart Journal, 2021, 42, 555-557.	2.2	2
35	The Assessment of Scales of Frailty and Physical Performance Improves Prediction of Major Adverse Cardiac Events in Older Adults with Acute Coronary Syndrome. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1113-1119.	3.6	49
36	ARNIs: balancing "the good and the bad―of neuroendocrine response to HF. Clinical Research in Cardiology, 2020, 109, 599-610.	3.3	5

#	Article	IF	CITATIONS
37	Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. European Journal of Preventive Cardiology, 2020, 27, 426-436.	1.8	21
38	Nutritional status and all-cause mortality in older adults with acute coronary syndrome. Clinical Nutrition, 2020, 39, 1572-1579.	5.0	35
39	From left ventricular ejection fraction to cardiac hemodynamics: role of echocardiography in evaluating patients with heart failure. Heart Failure Reviews, 2020, 25, 217-230.	3.9	27
40	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. European Heart Journal, 2020, 41, 347-356.	2.2	55
41	Sex―and age―elated differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 92-102.	7.1	81
42	Echocardiographic Evaluation of Left Ventricular Output in Patients with Heart Failure: A Per-Beat or Per-Minute Approach?. Journal of the American Society of Echocardiography, 2020, 33, 135-147.e3.	2.8	22
43	Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry. Journal of Clinical Medicine, 2020, 9, 4.	2.4	17
44	The journey of omega-3 fatty acids in cardiovascular medicine. European Heart Journal Supplements, 2020, 22, J49-J53.	0.1	3
45	Current Role of Echocardiography in Cardiac Resynchronization Therapy: from Cardiac Mechanics to Flow Dynamics Analysis. Current Heart Failure Reports, 2020, 17, 384-396.	3.3	9
46	Aortic Valve Stenosis and Mitochondrial Dysfunctions: Clinical and Molecular Perspectives. International Journal of Molecular Sciences, 2020, 21, 4899.	4.1	20
47	What Happened to Electrocardiogram as aÂScreening Test to Recognize Cardiovascular Complications in COVID-19 Patients?. Journal of the American College of Cardiology, 2020, 76, 2799-2800.	2.8	0
48	COX-2 Is Downregulated in Human Stenotic Aortic Valves and Its Inhibition Promotes Dystrophic Calcification. International Journal of Molecular Sciences, 2020, 21, 8917.	4.1	8
49	Right Atrial Pressure Is Associated with Outcomes in Patients with Heart Failure and Indeterminate Left Ventricular Filling Pressure. Journal of the American Society of Echocardiography, 2020, 33, 1345-1356.	2.8	9
50	Adapting to survive. European Heart Journal, 2020, 41, 3981-3983.	2.2	0
51	Electrocardiographic features of 431 consecutive, critically ill COVID-19 patients: an insight into the mechanisms of cardiac involvement. Europace, 2020, 22, 1848-1854.	1.7	74
52	Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2020, 396, 830-838.	13.7	44
53	Beta-blockers and COPD: how can harmony be restored in a marriage in crisis?. European Heart Journal, 2020, 41, 4423-4424.	2.2	2
54	Novel Echocardiographic Approach to Hemodynamic Phenotypes Predicts Outcome of Patients Hospitalized With Heart Failure. Circulation: Cardiovascular Imaging, 2020, 13, e009939.	2.6	14

#	Article	IF	CITATIONS
55	The â€~Black Death' and the physician at the time of COVID-19. European Heart Journal, 2020, 41, 3501-3502	2.2.2	3
56	COVID-19 in the heart and the lungs: could we "Notch―the inflammatory storm?. Basic Research in Cardiology, 2020, 115, 31.	5.9	160
57	Paradoxical low-flow phenotype in hospitalized heart failure with preserved ejection fraction. IJC Heart and Vasculature, 2020, 28, 100539.	1.1	1
58	Response by Mele et al to Letter Regarding Article, "Novel Echocardiographic Approach to Hemodynamic Phenotypes Predicts Outcome of Patients Hospitalized With Heart Failure― Circulation: Cardiovascular Imaging, 2020, 13, e011045.	2.6	1
59	Lamin A/C Missense Mutation R216C Pinpoints Overlapping Features Between Brugada Syndrome and Laminopathies. Circulation Genomic and Precision Medicine, 2020, 13, e002751.	3.6	6
60	2019 guidelines for the diagnosis and management of chronic coronary syndromes: congratulations and criticism. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 331-332.	3.0	3
61	Reply to the new ESC guidelines for the diagnosis and management of chronic coronary syndromes: Can we use them in practice?. International Journal of Cardiology, 2020, 305, 42.	1.7	0
62	Understanding the results of the PARAGONâ€HF trial. European Journal of Heart Failure, 2020, 22, 1531-1535.	7.1	7
63	Ticagrelor Increases SIRT1 and HES1 mRNA Levels in Peripheral Blood Cells from Patients with Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease. International Journal of Molecular Sciences, 2020, 21, 1576.	4.1	20
64	Sodium–glucose coâ€ŧransporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	7.1	100
65	COVID-19 testing. European Heart Journal, 2020, 41, 2427-2428.	2.2	2
66	The battle against COVID-19: mortality in Italy. European Heart Journal, 2020, 41, 2050-2052.	2.2	20
67	Living with stable angina: patients' pathway and needs in angina. Journal of Cardiovascular Medicine, 2020, 21, 377-382.	1.5	6
68	The Cardiologist at the time of Coronavirus: a perfect storm. European Heart Journal, 2020, 41, 1320-1322.	2.2	4
69	Priorities for Cath labs in the COVID-19 tsunami. European Heart Journal, 2020, 41, 1784-1785.	2.2	7
70	Key words to be adopted for COVID-19 research. European Heart Journal, 2020, 41, 4229-4230.	2.2	4
71	Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective <scp>CLARIFY</scp> registry. European Journal of Heart Failure, 2020, 22, 804-812.	7.1	9
72	Cardiovascular risk of chronic coronary syndrome patients according to vascular phenotype, diabetes, and smoking. European Journal of Preventive Cardiology, 2020, , .	1.8	0

#	Article	IF	CITATIONS
73	Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach. Drugs, 2019, 79, 1543-1556.	10.9	11
74	Right Ventricle Function in Patients with Acute Coronary Syndrome and Concomitant Undiagnosed Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 284-291.	1.6	4
75	The Notch pathway: a novel therapeutic target for cardiovascular diseases?. Expert Opinion on Therapeutic Targets, 2019, 23, 695-710.	3.4	29
76	KRIT1 Deficiency Promotes Aortic Endothelial Dysfunction. International Journal of Molecular Sciences, 2019, 20, 4930.	4.1	24
77	Intracardiac flow analysis in cardiac resynchronization therapy: A new challenge?. Echocardiography, 2019, 36, 1919-1929.	0.9	7
78	A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI) Tj ETQq0 0	0 r gB T /Ov	verlæck 10 Tf S
79	Prognosis after pacemaker implantation in extreme elderly. European Journal of Internal Medicine, 2019, 65, 37-43.	2.2	5
80	New onset of chest pain: the importance of remote monitoring. European Heart Journal Supplements, 2019, 21, C32-C36.	0.1	0
81	Understanding ARNIs. European Heart Journal, 2019, 40, 1397-1398.	2.2	2
82	The multifaceted angina. European Heart Journal Supplements, 2019, 21, C1-C5.	0.1	3
83	Angina and chronic obstructive pulmonary disease: facing the perfect storm. European Heart Journal Supplements, 2019, 21, C17-C20.	0.1	3
84	Angina and left ventricular dysfunction: can we â€~reduce' it?. European Heart Journal Supplements, 2019, 21, C28-C31.	0.1	0
85	Effectiveness of a Novel Nutraceutical Compound Containing Red Yeast Rice, Polymethoxyflavones and Antioxidants in the Modulation of Cholesterol Levels in Subjects With Hypercholesterolemia and Low-Moderate Cardiovascular Risk: The NIRVANA Study. Frontiers in Physiology, 2019, 10, 217.	2.8	13
86	Living alone and cardiovascular disease outcomes. Heart, 2019, 105, 1087-1095.	2.9	26
87	Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2019, 73, 1362-1364.	2.8	34
88	Exosome in Cardiovascular Diseases: A Complex World Full of Hope. Cells, 2019, 8, 166.	4.1	103
89	Treating angina. European Heart Journal Supplements, 2019, 21, G1-G3.	0.1	1
90	Anti-anginal drugs–beliefs and evidence: systematic review covering 50 years of medical treatment. European Heart Journal, 2019, 40, 190-194.	2.2	49

#	Article	IF	CITATIONS
91	β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. European Heart Journal, 2019, 40, 1399-1407.	2.2	66
92	CHA2DS2â€VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled metaâ€analysis. Clinical Cardiology, 2019, 42, 358-364.	1.8	16
93	Grip strength predicts cardiac adverse events in patients with cardiac disorders: an individual patient pooled meta-analysis. Heart, 2019, 105, 834-841.	2.9	61
94	Intracardiac Flow Analysis: Techniques and Potential Clinical Applications. Journal of the American Society of Echocardiography, 2019, 32, 319-332.	2.8	56
95	Anti-anginal drugs: Systematic review and clinical implications. International Journal of Cardiology, 2019, 283, 55-63.	1.7	23
96	Acute heart failure: lessons learned, roads ahead. European Journal of Heart Failure, 2018, 20, 842-850.	7.1	17
97	The Impact of Surgical and Trans-Catheter Aortic Valve Replacement on Endothelial Function: New Markers Ahead. , 2018, , 359-366.		0
98	Major unmet needs in the cardiovascular area. European Heart Journal Supplements, 2018, 20, C4-C7.	0.1	0
99	Ferrara IV. European Heart Journal, 2018, 39, 497-501.	2.2	4
100	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment–Elevation Myocardial Infarction and Multivessel Disease. Circulation: Cardiovascular Interventions, 2018, 11, e006023.	3.9	80
101	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. European Journal of Preventive Cardiology, 2018, 25, 377-387.	1.8	12
102	Beyond cardiomyocyte loss: Role of Notch in cardiac aging. Journal of Cellular Physiology, 2018, 233, 5670-5683.	4.1	11
103	Left ventricular ejection fraction and heart failure: an indissoluble marriage?. European Journal of Heart Failure, 2018, 20, 427-430.	7.1	50
104	Echocardiographic evaluation of cardiac dyssynchrony: Does it still matter?. Echocardiography, 2018, 35, 707-715.	0.9	11
105	Ferrara V. European Heart Journal, 2018, 39, 977-981.	2.2	2
106	Role of ivabradine in management of stable angina in patients with different clinical profiles. Open Heart, 2018, 5, e000725.	2.3	10
107	Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension. Hypertension, 2018, 71, 168-176.	2.7	41
108	Characteristics, treatments and 1â€year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2018, 20, 100-110.	7.1	86

#	Article	IF	CITATIONS
109	A 'diamond' approach to personalized treatment of angina. Nature Reviews Cardiology, 2018, 15, 120-132.	13.7	105
110	Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients. European Journal of Internal Medicine, 2018, 47, 82-86.	2.2	12
111	Full Sternotomy, Hemisternotomy, and Minithoracotomy for Aortic Valve Surgery: Is There a Difference?. Annals of Thoracic Surgery, 2018, 106, 1782-1788.	1.3	28
112	Ferrara III. European Heart Journal, 2018, 39, 88-90.	2.2	3
113	Evaluation of left ventricular systolic function during atrial fibrillation: Is it reliable?. International Journal of Cardiology, 2018, 263, 63-64.	1.7	3
114	Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F ₁ /F _O -Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction. Journal of Medicinal Chemistry, 2018, 61, 7131-7143.	6.4	41
115	Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF). Frontiers in Physiology, 2018, 9, 337.	2.8	25
116	Physical activity intervention for elderly patients with reduced physical performance after acute coronary syndrome (HULK study): rationale and design of a randomized clinical trial. BMC Cardiovascular Disorders, 2018, 18, 98.	1.7	22
117	New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma. Frontiers in Oncology, 2018, 8, 91.	2.8	46
118	Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis. Systematic Reviews, 2018, 7, 131.	5.3	4
119	Are all children born the same?. European Heart Journal, 2018, 39, 3411-3415.	2.2	0
120	Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. European Heart Journal, 2018, 39, 3855-3863.	2.2	21
121	Treatment of Angina: Where Are We?. Cardiology, 2018, 140, 52-67.	1.4	48
122	Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study. Cardiology, 2018, 140, 74-82.	1.4	6
123	Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery Disease. American Journal of Medicine, 2017, 130, 720-730.	1.5	38
124	Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis. Chronic Respiratory Disease, 2017, 14, 117-126.	2.4	43
125	Noninvasive evaluation of right hemodynamics in carcinoid heart disease: A case report. Journal of Clinical Ultrasound, 2017, 45, 355-361.	0.8	0
126	Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care, 2017, 40, 671-678.	8.6	103

#	Article	IF	CITATIONS
127	Mutation Load of Multiple Ion Channel Gene Mutations in Brugada Syndrome. Cardiology, 2017, 137, 256-260.	1.4	30
128	Operator, Drug or Device: Who Will Break Down Acute Stent Thrombosis?. Cardiology, 2017, 137, 244-245.	1.4	0
129	Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the <scp>ESC</scp> Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2017, 19, 1242-1254.	7.1	339
130	A Clinical Case of Catecholaminergic Polymorphic Ventricular Tachycardia: The Clinical Suspicious and the Need of Genetics. Cardiology, 2017, 138, 69-72.	1.4	1
131	Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. International Journal of Cardiology, 2017, 244, 59-66.	1.7	21
132	Mitochondrial permeability transition involves dissociation of F ₁ <scp>F_O ATP</scp> synthase dimers and Câ€ring conformation. EMBO Reports, 2017, 18, 1077-1089.	4.5	163
133	Rationale, design, and baseline characteristics of the <scp>CLARIFY</scp> registry of outpatients with stable coronary artery disease. Clinical Cardiology, 2017, 40, 797-806.	1.8	40
134	Epidemiology and oneâ€year outcomes in patients with chronic heart failure and preserved, midâ€range and reduced ejection fraction: an analysis of the ESC Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2017, 19, 1574-1585.	7.1	568
135	Extracorporeal Circulatory Support in Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. Critical Care Medicine, 2017, 45, e1173-e1183.	0.9	26
136	Estrogen receptor β–dependent Notch1 activation protects vascular endothelium against tumor necrosis factor α (TNFα)-induced apoptosis. Journal of Biological Chemistry, 2017, 292, 18178-18191.	3.4	52
137	Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention. Data in Brief, 2017, 14, 197-205.	1.0	13
138	Left Ventricular Lead Position Guided by Parametric Strain Echocardiography Improves Response to Cardiac Resynchronization Therapy. Journal of the American Society of Echocardiography, 2017, 30, 1001-1011.	2.8	18
139	Distinct gene expression profiles associated with Notch ligands Delta-like 4 and Jagged1 in plaque material from peripheral artery disease patients: a pilot study. Journal of Translational Medicine, 2017, 15, 98.	4.4	26
140	Inâ€hospital and 1â€year mortality associated with diabetes in patients with acute heart failure: results from the <scp>ESCâ€HFA</scp> Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2017, 19, 54-65.	7.1	150
141	The frailty in elderly patients receiving cardiac interventional procedures (FRASER) program: rational and design of a multicenter prospective study. Aging Clinical and Experimental Research, 2017, 29, 895-903.	2.9	19
142	The European Society of Cardiology ACCA-EAPCI Registry on ST elevation myocardial infarction. European Heart Journal, 2017, 38, 138-139.	2.2	3
143	Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. Thrombosis and Haemostasis, 2017, 117, 1208-1216.	3.4	50
144	Current role of echocardiography in cardiac resynchronization therapy. Heart Failure Reviews, 2017, 22, 699-722.	3.9	14

#	Article	IF	CITATIONS
145	Reperfusion Damage ― A Story of Success, Failure, and Hope ―. Circulation Journal, 2017, 81, 131-141.	1.6	42
146	Ferrara I: Introduction. European Heart Journal, 2017, 38, 3255-3257.	2.2	6
147	Ferrara II. European Heart Journal, 2017, 38, 3337-3339.	2.2	3
148	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic–therapeutic pathway in Italy. European Heart Journal Supplements, 2017, 19, D3-D54.	0.1	19
149	A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. PLoS ONE, 2017, 12, e0182124.	2.5	12
150	Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus non-cardiologists: the international prospective CLARIFY registry. Polish Archives of Internal Medicine, 2017, 127, 107-114.	0.4	2
151	Remodelling after an Infarct: Crosstalk between Life and Death. Cardiology, 2016, 135, 68-76.	1.4	9
152	Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings. International Journal of Cardiology, 2016, 221, 993-997.	1.7	26
153	European Society of Cardiology Heart Failure Longâ€Term Registry (<scp>ESCâ€HFâ€LT</scp>): 1â€year followâ€up outcomes and differences across regions. European Journal of Heart Failure, 2016, 18, 613-625.	7.1	538
154	Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 859-868.	7.1	36
155	Can We Improve Myocardial Protection during Ischaemic Injury?. Cardiology, 2016, 135, 14-26.	1.4	11
156	Heart failure: an historical perspective. European Heart Journal Supplements, 2016, 18, G3-G10.	0.1	19
157	Short Physical Performance Battery and all-cause mortality: systematic review and meta-analysis. BMC Medicine, 2016, 14, 215.	5.5	534
158	Heart rate reduction in coronary artery disease and heart failure. Nature Reviews Cardiology, 2016, 13, 493-501.	13.7	68
159	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European Heart Journal Supplements, 2016, 18, C2-C12.	0.1	71
160	Individualized Angiotensinâ€Converting Enzyme (ACE)â€Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model. Journal of the American Heart Association, 2016, 5, e002688.	3.7	16
161	Residual cardiovascular risk. European Heart Journal Supplements, 2016, 18, C1-C1.	0.1	8
162	Heart, lung, and vascular registries: Evolving goals, successful approaches, and ongoing innovation. Journal of Heart and Lung Transplantation, 2016, 35, 1149-1157.	0.6	26

#	Article	IF	CITATIONS
163	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet, The, 2016, 388, 2142-2152.	13.7	357
164	Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history. International Journal of Cardiology, 2016, 222, 806-812.	1.7	17
165	Cardiac resynchronization therapy guided by multimodality cardiac imaging. European Journal of Heart Failure, 2016, 18, 1375-1382.	7.1	58
166	Fractional Flow Reserve Evaluation and Chronic Kidney Disease: Analysis From a Multicenter <scp>I</scp> talian Registry (the <scp>FREAK</scp> Study). Catheterization and Cardiovascular Interventions, 2016, 88, 555-562.	1.7	40
167	Current views on anthracycline cardiotoxicity. Heart Failure Reviews, 2016, 21, 621-634.	3.9	39
168	Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparison. International Journal of Cardiovascular Imaging, 2016, 32, 211-223.	1.5	15
169	International cooperation in healthcare: model of IRCCS Policlinico San Donato and Bambini Cardiopatici nel Mondo Association for congenital heart diseases. European Heart Journal Supplements, 2016, 18, E72-E78.	0.1	10
170	How can the European Society of Cardiology ensure compliance with ethical standards?. European Heart Journal, 2016, 37, 741-744.	2.2	4
171	Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. Platelets, 2016, 27, 484-487.	2.3	32
172	Management of the hypertensive patient with elevated heart rate. Journal of Hypertension, 2016, 34, 813-821.	0.5	116
173	Reincarnated medicines: using out-dated drugs for novel indications. European Heart Journal, 2016, 37, 2571-2576.	2.2	11
174	Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients. Ultrasound in Medicine and Biology, 2016, 42, 125-132.	1.5	14
175	Quality of Life With Ivabradine in Patients With Angina Pectoris. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 31-38.	2.2	15
176	Antiplatelet Treatment Reduces All-Cause Mortality in COPD Patients: A Systematic Review and Meta-Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 509-514.	1.6	48
177	Polar plot maps by parametric strain echocardiography allow accurate evaluation of non-viable transmural scar tissue in ischaemic heart disease. European Heart Journal Cardiovascular Imaging, 2016, 17, 668-677.	1.2	20
178	An update on atrial fibrillation in 2014: From pathophysiology to treatment. International Journal of Cardiology, 2016, 203, 22-29.	1.7	56
179	Remote monitoring of implantable devices: Should we continue to ignore it?. International Journal of Cardiology, 2016, 202, 368-377.	1.7	27
180	Uric acid and coronary artery disease: An elusive link deserving further attention. International Journal of Cardiology, 2016, 213, 28-32.	1.7	57

#	Article	IF	CITATIONS
181	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). European Heart Journal, 2016, 37, 152-160.	2.2	29
182	Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: Analysis of the CLARIFY registry. Medicina (Lithuania), 2015, 51, 240-246.	2.0	6
183	Dual Antiplatelet Therapy in Patients with Glucose-6-Phosphate Dehydrogenase Deficiency undergoing PCI with Drug-Eluting Stents. Journal of Atherosclerosis and Thrombosis, 2015, 22, 535-541.	2.0	10
184	Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. PLoS ONE, 2015, 10, e0125164.	2.5	15
185	Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker?. Thrombosis and Haemostasis, 2015, 114, 123-132.	3.4	23
186	Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis. International Journal of Cardiology, 2015, 191, 187-193.	1.7	69
187	Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-operation and Development Health Systems: Findings Based on the Long-Term Registry of the European Society of Cardiology on Heart Failure. Value in Health, 2015, 18, 1098-1104.	0.3	11
188	Ivabradine in the management of coronary artery disease with or without left ventricular dysfunction or heart failure. European Heart Journal Supplements, 2015, 17, G24-G29.	0.1	2
189	The ivabradine journey: TableÂ1. European Heart Journal Supplements, 2015, 17, G1-G9.	0.1	1
190	Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease — Results from EUROPA. International Journal of Cardiology, 2015, 182, 194-199.	1.7	11
191	Cancer Therapy-Induced Cardiotoxicity: Role of Ultrasound Deformation Imaging as an Aid to Early Diagnosis. Ultrasound in Medicine and Biology, 2015, 41, 627-643.	1.5	28
192	Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction. American Journal of Medicine, 2015, 128, 1102-1108.e6.	1.5	24
193	The Role of Notch in the Cardiovascular System: Potential Adverse Effects of Investigational Notch Inhibitors. Frontiers in Oncology, 2015, 4, 384.	2.8	33
194	Enhanced stent visualization systems during PCI: A case series and review of literature. Journal of Cardiology Cases, 2015, 12, 1-5.	0.5	12
195	Platelet aggregation values in patients with cardiovascular risk factors are reduced by verbascoside treatment. A randomized study. Pharmacological Research, 2015, 97, 1-6.	7.1	30
196	SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research, 2015, 12, 90-100.	2.0	333
197	Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. European Heart Journal, 2015, 36, ehv451.	2.2	37
198	The role of heart rate may differ according to pathophysiological setting: from SHIFT to SIGNIFY. European Heart Journal, 2015, 36, 2042-2046.	2.2	18

#	Article	IF	CITATIONS
199	Heart failure with preserved ejection fraction: uncertainties and dilemmas. European Journal of Heart Failure, 2015, 17, 665-671.	7.1	124
200	Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry. European Journal of Preventive Cardiology, 2015, 22, 1056-1065.	1.8	50
201	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy. Atherosclerosis Supplements, 2015, 19, 1-12.	1.2	66
202	Perindopril and Î ² -blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. American Heart Journal, 2015, 170, 1092-1098.	2.7	22
203	Prevention and Control of Cardiovascular Diseases: Integrated and Complimentary Strategies. , 2015, , 219-226.		Ο
204	A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study. Current Pharmacogenomics and Personalized Medicine, 2015, 12, 159-166.	0.2	0
205	Heart rate and use of β-blockers in Mexican stable outpatients with coronary artery disease. Archivos De Cardiologia De Mexico, 2015, 85, 270-277.	0.2	7
206	European Heart for Children: a story of humanity and success. European Heart Journal, 2015, 36, 1789-90.	2.2	1
207	Ivabradine in Stable Coronary Artery Disease. New England Journal of Medicine, 2014, 371, 2435-2435.	27.0	16
208	Prevalence of Anginal Symptoms and Myocardial Ischemia and Their Effect on Clinical Outcomes in Outpatients With Stable Coronary Artery Disease. JAMA Internal Medicine, 2014, 174, 1651.	5.1	118
209	On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention: TableÂ1. Thorax, 2014, 69, 80-81.	5.6	28
210	In VitroEndothelial Cell Proliferation Assay Reveals Distinct Levels of Proangiogenic Cytokines Characterizing Sera of Healthy Subjects and of Patients with Heart Failure. Mediators of Inflammation, 2014, 2014, 1-11.	3.0	12
211	Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. European Heart Journal, 2014, 35, 612-623.	2.2	160
212	Insufficient control of heart rate in stable coronary artery disease patients in Latvia. Medicina (Lithuania), 2014, 50, 295-302.	2.0	3
213	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	1.4	2,164
214	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. European Heart Journal, 2014, 35, 2383-2431.	2.2	1,253
215	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOMEâ,,¢). Cardiovascular Diabetology, 2014, 13, 102. 	6.8	198
216	Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. International Journal of Cardiology, 2014, 177, 711-713.	1.7	5

#	Article	IF	CITATIONS
217	Impact of Chronic Kidney Disease on Use of Evidence-Based Therapy in Stable Coronary Artery Disease: A Prospective Analysis of 22,272 Patients. PLoS ONE, 2014, 9, e102335.	2.5	21
218	Demographic and Clinical Characteristics of Patients With Stable Coronary Artery Disease: Results From the CLARIFY Registry in Spain. Revista Espanola De Cardiologia (English Ed), 2014, 67, 538-544.	0.6	12
219	Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis. Journal of the American College of Cardiology, 2014, 63, 506-512.	2.8	58
220	Alteration of Notch signaling and functionality of adipose tissue derived mesenchymal stem cells in heart failure. International Journal of Cardiology, 2014, 174, 119-126.	1.7	12
221	CardioPulse Articles. European Heart Journal, 2014, 35, 1223-1230.	2.2	0
222	GuÃa de práctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Revista Espanola De Cardiologia, 2014, 67, 136.e1-136.e56.	1.2	15
223	Transradial Coronary Catheterization and Intervention Across the Whole Spectrum of Allen Test Results. Journal of the American College of Cardiology, 2014, 63, 1833-1841.	2.8	123
224	Use of ACE inhibitors in stable CAD—what is the truth?. Nature Reviews Cardiology, 2014, 11, 315-316.	13.7	3
225	Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure. New England Journal of Medicine, 2014, 371, 1091-1099.	27.0	399
226	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.2	3,469
227	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.2	4,141
228	Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. International Journal of Cardiology, 2014, 176, 119-124.	1.7	30
229	The Notch pathway: a novel target for myocardial remodelling therapy?. European Heart Journal, 2014, 35, 2140-2145.	2.2	46
230	Management of outpatients in France with stable coronary artery disease. Findings from the prospeCtive observational LongitudinAl Registry oF patients with stable coronary arterY disease (CLARIFY) registry. Archives of Cardiovascular Diseases, 2014, 107, 452-461.	1.6	12
231	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	2.2	2,591
232	CaracterÃsticas demográficas y clÃnicas de los pacientes con enfermedad coronaria estable: resultados del registro CLARIFY en España. Revista Espanola De Cardiologia, 2014, 67, 538-544.	1.2	18
233	Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODICY trial substudy. International Journal of Cardiology, 2014, 173, 343-345.	1.7	7
234	Ivabradine: Heart Rate and Left Ventricular Function. Cardiology, 2014, 128, 226-230.	1.4	16

#	Article	IF	CITATIONS
235	The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. Expert Review of Cardiovascular Therapy, 2013, 11, 705-717.	1.5	39
236	Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. International Journal of Cardiology, 2013, 167, 296-297.	1.7	10
237	The Notch pathway: a crossroad between the life and death of the endothelium. European Heart Journal, 2013, 34, 2504-2509.	2.2	51
238	Open-Label, Randomized, Placebo-Controlled Evaluation of Intracoronary Adenosine or Nitroprusside After Thrombus Aspiration During Primary Percutaneous Coronary Intervention for the Prevention of Microvascular Obstruction in Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2013, 6, 580-589.	2.9	100
239	Coagulation Factors and Recurrence of Ischemic and Bleeding Adverse Events in Patients with Acute Coronary Syndromes. Thrombosis Research, 2013, 132, 151-157.	1.7	22
240	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	2.2	1,758
241	Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure. Respirology, 2013, 18, 125-130.	2.3	26
242	Pacing transmural scar tissue reduces left ventricle reverse remodeling after cardiac resynchronization therapy. International Journal of Cardiology, 2013, 167, 94-101.	1.7	22
243	Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease. International Journal of Cardiology, 2013, 167, 2938-2943.	1.7	64
244	Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. American Heart Journal, 2013, 166, 654-661.e6.	2.7	27
245	Kounis–Zavras syndrome presenting with ventricular arrhythmias and cardiogenic shock. Journal of Cardiology Cases, 2013, 7, e74-e77.	0.5	3
246	Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). International Journal of Cardiology, 2013, 165, 134-141.	1.7	29
247	Development and Validation of a Cardiovascular Risk Assessment Model in Patients With Established Coronary Artery Disease. American Journal of Cardiology, 2013, 112, 27-33.	1.6	26
248	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	2.2	5,681
249	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. European Heart Journal, 2013, 34, 2263-2270.	2.2	85
250	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	2.2	3,915
251	Revising common beliefs in the management of stable CAD. Nature Reviews Cardiology, 2013, 10, 65-66.	13.7	8
252	Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). European Heart Journal, 2013, 34, 909-919.	2.2	108

#	Article	IF	CITATIONS
253	RAAS inhibition and mortality in hypertension. Global Cardiology Science & Practice, 2013, 2013, 34.	0.4	19
254	The role of Notch pathway in cardiovascular diseases. Global Cardiology Science & Practice, 2013, 2013, 44.	0.4	12
255	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	2.2	2,176
256	17β-Estradiol Enhances Signalling Mediated by VEGF-A-Delta-Like Ligand 4-Notch1 Axis in Human Endothelial Cells. PLoS ONE, 2013, 8, e71440.	2.5	52
257	In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome. PLoS ONE, 2013, 8, e56377.	2.5	29
258	The role of Notch pathway in cardiovascular diseases. Global Cardiology Science & Practice, 2013, 2013, 364-71.	0.4	18
259	Inhibicja RAAS a śmiertelność w nadciśnieniu tętniczym: od farmakologii do dowodów klinicznych. Kardiologia Polska, 2013, 71, 1-7.	0.6	1
260	RAAS inhibition and mortality in hypertension: from pharmacology to clinical evidence. Kardiologia Polska, 2013, 71, 1-7.	0.6	14
261	Thrombin generation assay. Blood Coagulation and Fibrinolysis, 2012, 23, 680-687.	1.0	22
262	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. European Journal of Heart Failure, 2012, 14, 1056-1066.	7.1	105
263	Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Circulation, 2012, 125, 2015-2026.	1.6	640
264	Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. European Heart Journal, 2012, 33, 2831-2840.	2.2	560
265	PERTINENT: AUTHORS' RETROSPECTIVE. Cardiovascular Research, 2012, 96, 204-207.	3.8	2
266	Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). European Heart Journal, 2012, 33, 2910-2916.	2.2	40
267	The in vitro effects of verbascoside on human platelet aggregation. Journal of Thrombosis and Thrombolysis, 2012, 34, 318-325.	2.1	21
268	Our Time: A Call to Save Preventable Death From Cardiovascular Disease (Heart Disease and Stroke). Circulation, 2012, 126, 2769-2775.	1.6	157
269	Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial. American Heart Journal, 2012,	2.7	13
270	Pro-inflammatory genetic profile and familiarity of acute myocardial infarction. Immunity and Ageing, 2012, 9, 14.	4.2	23

#	Article	IF	CITATIONS
271	Prasugrel Versus Tirofiban Bolus With or Without Short Post-Bolus Infusion With or Without Concomitant Prasugrel Administration in Patients With Myocardial Infarction Undergoing Coronary Stenting. JACC: Cardiovascular Interventions, 2012, 5, 268-277.	2.9	162
272	Our Time: A Call to Save Preventable Death From Cardiovascular Disease (Heart Disease and Stroke). Journal of the American College of Cardiology, 2012, 60, 2343-2348.	2.8	130
273	Heart Rate and Use of Beta-Blockers in Stable Outpatients with Coronary Artery Disease. PLoS ONE, 2012, 7, e36284.	2.5	70
274	Longâ€ŧerm treatment with ivabradine in postâ€myocardial infarcted rats counteracts fâ€channel overexpression. British Journal of Pharmacology, 2012, 165, 1457-1466.	5.4	55
275	Our Time: A Call to Save Preventable Death From Cardiovascular Disease (Heart Disease and Stroke). Global Heart, 2012, 7, 297.	2.3	35
276	Does the site of bleeding matter? A stratified analysis on Flocation of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. EuroIntervention, 2012, 8, 71-78.	3.2	25
277	Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 57, 2474-2483.	2.8	315
278	ACE Inhibition Modulates Endothelial Apoptosis and Renewal via Endothelial Progenitor Cells in Patients with Acute Coronary Syndromes. American Journal of Cardiovascular Drugs, 2011, 11, 189-198.	2.2	40
279	Genetic determinants of on-clopidogrel high platelet reactivity. Platelets, 2011, 22, 399-407.	2.3	48
280	Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. International Journal of Cardiology, 2011, 146, 408-414.	1.7	80
281	Selective and specific <i>I</i> _f inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease. Expert Review of Cardiovascular Therapy, 2011, 9, 959-973.	1.5	15
282	Heart rate: a forgotten link in coronary artery disease?. Nature Reviews Cardiology, 2011, 8, 369-379.	13.7	73
283	The Mediterranean diet: a cultural journey. Lancet, The, 2011, 377, 1730-1731.	13.7	13
284	The Mediterranean diet: a cultural journey – Authors' reply. Lancet, The, 2011, 378, 767.	13.7	0
285	A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. Journal of Hypertension, 2011, 29, 509-519.	0.5	47
286	Different Image Integration Modalities to Guide AF Ablation: Impact on Procedural and Fluoroscopy Times. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 422-430.	1.2	32
287	Circulating stem cell vary with NYHA stage in heart failure patients. Journal of Cellular and Molecular Medicine, 2011, 15, 1726-1736.	3.6	27
288	Safety of Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction (from the BEAUTIFUL Holter Substudy). American Journal of Cardiology, 2011, 107, 805-811.	1.6	34

#	Article	IF	CITATIONS
289	Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina. Cardiovascular Drugs and Therapy, 2011, 25, 531-537.	2.6	61
290	Different clinical models of CD34Â+Âcells mobilization in patients with cardiovascular disease. Journal of Thrombosis and Thrombolysis, 2011, 32, 1-8.	2.1	12
291	Persistent Coronary No Flow After Wire Insertion Is an Early and Readily Available Mortality Risk Factor Despite Successful Mechanical Intervention in Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2011, 4, 51-62.	2.9	29
292	The heart rate story. European Heart Journal Supplements, 2011, 13, C4-C13.	0.1	15
293	Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H366-H373.	3.2	47
294	TNF-α modulates the migratory response of mesenchymal stem cells to TRAIL. Cellular and Molecular Life Sciences, 2010, 67, 1307-1314.	5.4	19
295	Secondary Prevention of CAD with ACE Inhibitors: A Struggle Between Life and Death of the Endothelium. Cardiovascular Drugs and Therapy, 2010, 24, 331-339.	2.6	41
296	Poor response to clopidogrel: current and future options for its management. Journal of Thrombosis and Thrombolysis, 2010, 30, 319-331.	2.1	53
297	Noncontact Mapping of Left Ventricle during CRT Implant. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 74-84.	1.2	7
298	Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. Journal of Blood Medicine, 2010, 1, 61.	1.7	2
299	European Heart for Children. European Journal of Cardiovascular Nursing, 2010, 9, 199-200.	0.9	0
300	Response to Letter Regarding Article, "Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study― Circulation, 2010, 121,	1.6	0
301	Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 591-593.	1.7	5
302	Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. European Heart Journal, 2010, 31, 1854-1864.	2.2	70
303	Evaluation of Platelet Inhibition by Tirofiban in Patients Stratified According to Aspirin and Clopidogrel Responsiveness. Journal of the American College of Cardiology, 2010, 55, 255-256.	2.8	16
304	Long-Term Clinical Outcome Based on Aspirin and Clopidogrel Responsiveness Status After Elective Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2010, 56, 1447-1455.	2.8	118
305	Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. American Heart Journal, 2010, 159, 795-802.	2.7	31
306	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention. American Heart Journal, 2010, 160, 804-811.	2.7	66

#	Article	IF	CITATIONS
307	An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis, 2010, 210, 274-277.	0.8	61
308	Metalloproteinase 2 cleaves in vitro recombinant TRAIL: Potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. Atherosclerosis, 2010, 211, 333-336.	0.8	30
309	Concerns and Hopes for Stem Cell Therapy in Cardiology: Focus on Endothelial Progenitor Cells. Cardiovascular & Hematological Disorders Drug Targets, 2010, 10, 216-223.	0.7	5
310	Potential Prognostic Significance of Decreased Serum Levels of TRAIL after Acute Myocardial Infarction. PLoS ONE, 2009, 4, e4442.	2.5	82
311	A modern fairy tale. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, S65-S67.	2.8	2
312	The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. European Heart Journal, 2009, 30, 1385-1394.	2.2	54
313	Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: the PREAMI echo sub-study. European Heart Journal, 2009, 30, 1656-1665.	2.2	17
314	Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. European Heart Journal, 2009, 30, 2337-2345.	2.2	192
315	Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. Cardiovascular Research, 2009, 84, 72-82.	3.8	42
316	Comparison of myocardial deformation and velocity dyssynchrony for identification of responders to cardiac resynchronization therapy. European Journal of Heart Failure, 2009, 11, 391-399.	7.1	24
317	Preface. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, S1-S1.	2.8	1
318	Temporal and Genotype-Driven Variation of Factor VII Levels in Patients With Acute Myocardial Infarction. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 119-122.	1.7	3
319	Radiofrequency ablation of paroxysmal atrial fibrillation by mesh catheter. Journal of Interventional Cardiac Electrophysiology, 2009, 25, 135-140.	1.3	5
320	Secondary Prevention of Coronary Disease with ACE Inhibition-does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?. Cardiovascular Drugs and Therapy, 2009, 23, 161-170.	2.6	27
321	Contact versus Noncontact Mapping for Ablation of Ventricular Tachycardia in Patients with Previous Myocardial Infarction. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 842-850.	1.2	8
322	Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention. Circulation, 2009, 119, 3215-3222.	1.6	213
323	Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: A subgroup analysis of the EUROPA trial. Archives of Cardiovascular Diseases, 2009, 102, 89-96.	1.6	10
324	The 5-Year Clinical Outcomes After a Randomized Comparison of Sirolimus-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2009, 54, 1900-1901.	2.8	38

#	Article	IF	CITATIONS
325	Insight into the Mode of Action of ACE Inhibition in Coronary Artery Disease. Drugs, 2009, 69, 265-277.	10.9	45
326	Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Expert Review of Cardiovascular Therapy, 2009, 7, 345-360.	1.5	22
327	ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study. Atherosclerosis, 2009, 204, 273-275.	0.8	24
328	Echocardiographic Myocardial Scar Burden Predicts Response to Cardiac Resynchronization Therapy in Ischemic Heart Failure. Journal of the American Society of Echocardiography, 2009, 22, 702-708.	2.8	44
329	Cardiovascular protection: a breakthrough for high-risk patients?. Journal of Hypertension, 2009, 27, S37-S40.	0.5	0
330	Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol. Journal of Cardiovascular Medicine, 2009, 10, 585-592	1.5	8
331	A step further with ivabradine: SIGNIfY (Study assessInG the morbidity-mortality beNefits of the If) Tj ETQq1 1 0. 2009, 11, D19-D27.	784314 rg 0.1	BT /Overlock 21
332	Mechanisms of Remodelling A Question of Life (Stem Cell Production) and Death (Myocyte Apoptosis). Circulation Journal, 2009, 73, 1973-1982.	1.6	38
333	Neuroendocrine Control of the Cardiovascular System in Heart Failure. , 2009, , 13-20.		0
334	Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design. Cardiovascular Drugs and Therapy, 2008, 22, 313-320.	2.6	25
335	Paroxysmal Atrial Fibrillation Ablation with the Multipolar Mapping and Ablation Catheter (Mesh-Bard). PACE - Pacing and Clinical Electrophysiology, 2008, 31, 753-756.	1.2	6
336	Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. Current Medical Research and Opinion, 2008, 24, 3543-3557.	1.9	23
337	A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. International Journal of Cardiology, 2008, 128, 53-61.	1.7	1
338	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 807-816.	13.7	934
339	Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet, The, 2008, 372, 817-821.	13.7	694
340	Abnormalities of Left Ventricular Function in Asymptomatic Patients with Systemic Sclerosis Using Doppler Measures of Myocardial Strain. Journal of the American Society of Echocardiography, 2008, 21, 1257-1264.	2.8	32
341	Radiofrequency Ablation of Atrial Fibrillation. Circulation, 2008, 117, 136-143.	1.6	102
342	Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction <subtitle>The MULTISTRATEGY Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2008, 299, 1788.	7.4	245

#	Article	IF	CITATIONS
343	Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. Current Opinion in Cardiology, 2008, 23, 296-301.	1.8	11
344	Radiofrequency atrial fibrillation ablation based on pathophysiology: a diversified protocol with long-term follow-up. Journal of Cardiovascular Medicine, 2008, 9, 68-75.	1.5	7
345	Abciximab: a reappraisal of its use in coronary care. Biologics: Targets and Therapy, 2008, 2, 29.	3.2	8
346	Relevance of apoptosis in influencing recovery of hibernating myocardium. European Journal of Heart Failure, 2007, 9, 377-383.	7.1	11
347	ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovascular Research, 2007, 73, 237-246.	3.8	146
348	Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart, 2007, 93, 1081-1086.	2.9	53
349	Left bundle branch block as a risk factor for progression to heart failure. European Journal of Heart Failure, 2007, 9, 7-14.	7.1	142
350	Radiofrequency catheter ablation to cure atrial fibrillation: may be a wrong target. Journal of Cardiovascular Medicine, 2007, 8, 718-719.	1.5	1
351	Implantable cardioverter defibrillators: from evidence of trials to clinical practice. Country Review Ukraine, 2007, 9, 166-173.	0.8	15
352	Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. American Heart Journal, 2007, 153, 629-635.	2.7	16
353	Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction. American Heart Journal, 2007, 154, 39-45.	2.7	15
354	Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function. International Journal of Cardiology, 2007, 121, 57-61.	1.7	15
355	Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial. Expert Review of Cardiovascular Therapy, 2007, 5, 1037-1046.	1.5	17
356	Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharmacological Research, 2007, 56, 42-48.	7.1	42
357	Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, 138-145.	2.8	78
358	Resting Heart Rate in Cardiovascular Disease. Journal of the American College of Cardiology, 2007, 50, 823-830.	2.8	867
359	Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?. Journal of the American College of Cardiology, 2007, 50, 1132-1137.	2.8	82
360	The Cardioprotective Effects of the Angiotensin-Converting Enzyme Inhibitor Perindopril in Patients With Stable Coronary Artery Disease Are Not Modified by Mild to Moderate Renal Insufficiency. Journal of the American College of Cardiology, 2007, 50, 2148-2155.	2.8	52

#	Article	IF	CITATIONS
361	Factor XIIIA-V34L and Factor XIIIB-H95R Gene Variants: Effects on Survival in Myocardial Infarction Patients. Molecular Medicine, 2007, 13, 112-120.	4.4	32
362	Percutaneous coronary injection of bone marrow cells in small experimental animals: Small is not too small. Pathology Research and Practice, 2007, 203, 801-808.	2.3	1
363	Sedation with Midazolam for Electrical Cardioversion. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 608-611.	1.2	15
364	Hibernating Myocardium: Diagnosis and Patient Outcomes. Current Problems in Cardiology, 2007, 32, 375-410.	2.4	328
365	Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. European Journal of Pharmacology, 2007, 577, 1-6.	3.5	75
366	Long-Term Effect of Perindopril on Coronary Atherosclerosis Progression (from the PERindopril's) Tj ETQq0 0 () rgBT /Ov 1.6	erlock 10 Tf 59
367	Differences in the Effect of Angiotensin-converting Enzyme Inhibitors on the Rate of Endothelial Cell Apoptosis: In Vitro and In Vivo Studies. Cardiovascular Drugs and Therapy, 2007, 21, 423-429.	2.6	49
368	Improved Detection of Left Ventricular Thrombi and Spontaneous Echocontrast by Tissue Harmonic Imaging in Patients with Myocardial Infarction. Journal of the American Society of Echocardiography, 2006, 19, 1373-1381.	2.8	7
369	Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention. Journal of the American College of Cardiology, 2006, 48, 2178-2185.	2.8	140
370	Anti-ischaemic effect of ivabradine. Pharmacological Research, 2006, 53, 435-439.	7.1	36
371	Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study. American Heart Journal, 2006, 152, 860-866.	2.7	79
372	Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: Time courses and prediction of response. Peptides, 2006, 27, 1776-1786.	2.4	44
373	Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?. European Heart Journal, 2006, 27, 2154-2157.	2.2	12
374	Aldosterone blockade in post-acute myocardial infarction heart failure. Clinical Cardiology, 2006, 29, 434-438.	1.8	4
375	ACE-Inhibition for Secondary Prevention of Cardiovascular Events—Should We Change Our Recommendation After PEACE?. Cardiovascular Drugs and Therapy, 2006, 20, 11-12.	2.6	3
376	Feasibility of the transseptal approach for fast and unstable left ventricular tachycardia mapping and ablation with a non-contact mapping system. Journal of Interventional Cardiac Electrophysiology, 2006, 16, 111-116.	1.3	10
377	Left intraventricular myocardial deformation dyssynchrony identifies responders to cardiac resynchronization therapy in patients with heart failure. European Heart Journal, 2006, 27, 1070-1078.	2.2	95
378	Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. European Heart Journal, 2006, 27, 796-801.	2.2	57

#	Article	IF	CITATIONS
379	One Heart, Two Lungs Together Forever. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 962-963.	5.6	4
380	Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives. Future Cardiology, 2006, 2, 17-27.	1.2	2
381	Effects of Angiotensin-Converting Enzyme Inhibition With Perindopril on Left Ventricular Remodeling and Clinical Outcome. Archives of Internal Medicine, 2006, 166, 659.	3.8	123
382	Tissue Factor and Coagulation Factor VII Levels During Acute Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2800-2806.	2.4	53
383	Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2005, 293, 2109.	7.4	290
384	Atrial Fibrillation and Recurrent Ventricular Fibrillation During Hypokalemia in Brugada Syndrome. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 1350-1353.	1.2	19
385	Incidence and outcome of persons with a clinical diagnosis of heart failure in a general practice population of 696,884 in the United Kingdom. European Journal of Heart Failure, 2005, 7, 295-302.	7.1	63
386	Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. European Heart Journal, 2005, 26, 1838-1845.	2.2	214
387	Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal, 2005, 26, 215-225.	2.2	1,392
388	Tumor Necrosis Factor-α Receptor 1 Is a Major Predictor of Mortality and New-Onset Heart Failure in Patients With Acute Myocardial Infarction. Circulation, 2005, 111, 863-870.	1.6	185
389	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. European Heart Journal, 2005, 26, 384-416.	2.2	1,114
390	Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. European Heart Journal, 2005, 26, 2232-2237.	2.2	246
391	White coats and fingerprints: diagnostic reasoning in medicine and investigative methods of fictional detectives. BMJ: British Medical Journal, 2005, 331, 1491-1494.	2.3	28
392	New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios. Country Review Ukraine, 2005, 7, K31-K35.	0.8	1
393	The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. European Heart Journal, 2005, 26, 1369-1378.	2.2	127
394	Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients. Country Review Ukraine, 2005, 7, H16-H21.	0.8	12
395	Acute haemodynamic effects of IL-6 treatment in vivo: Involvement of vagus nerve in NO-mediated negative inotropism. Cytokine, 2005, 30, 236-242.	3.2	10
396	Specific Properties and Effect of Perindopril in Controlling the Renin–Angiotensin System. American Journal of Hypertension, 2005, 18, 142-154.	2.0	35

#	Article	IF	CITATIONS
397	Effects of endotoxic shock on neuronal NOS and calcium transients in rat cardiac myocytes. Pharmacological Research, 2005, 51, 409-417.	7.1	21
398	Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Review of Cardiovascular Therapy, 2005, 3, 15-29.	1.5	58
399	Expert consensus document on ?-adrenergic receptor blockersThe Task Force on Beta-Blockers of the European Society of Cardiology. European Heart Journal, 2004, 25, 1341-1362.	2.2	465
400	CD34+and Endothelial Progenitor Cells in Patients With Various Degrees of Congestive Heart Failure. Circulation, 2004, 110, 1209-1212.	1.6	360
401	Oxidative Stress During Myocardial Ischaemia and Heart Failure. Current Pharmaceutical Design, 2004, 10, 1699-1711.	1.9	186
402	Assessment of left ventricular volume and function by integration of simplified 3D echocardiography, tissue harmonic imaging and automated extraction of endocardial borders. International Journal of Cardiovascular Imaging, 2004, 20, 191-202.	1.5	9
403	High-Dose BoluS TiRofibAn and Sirolimus Eluting STEnt versus Abiciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Study—Protocol Design and Demography of the First 100 Patients. Cardiovascular Drugs and Therapy, 2004, 18, 225-230.	2.6	15
404	Therapeutic Effects of lâ€Carnitine and Propionylâ€lâ€carnitine on Cardiovascular Diseases: A Review. Annals of the New York Academy of Sciences, 2004, 1033, 79-91.	3.8	208
405	TNF? in patients with congestive heart failure. Basic Research in Cardiology, 2004, 99, 12-17.	5.9	6
406	The prevalence of abnormal glucose regulation in patients with coronary artery disease across EuropeThe Euro Heart Survey on diabetes and the heart. European Heart Journal, 2004, 25, 1880-1890.	2.2	532
407	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversión de la angiotensina en la enfermedad cardiovascular. Revista Espanola De Cardiologia, 2004, 57, 1213-1232.	1.2	8
408	Improved recognition of dysfunctioning myocardial segments by longitudinal strain rate versus velocity in patients with myocardial infarction. Journal of the American Society of Echocardiography, 2004, 17, 313-321.	2.8	31
409	Effect of nolomirole on monocrotaline-induced heart failure. Pharmacological Research, 2004, 49, 1-5.	7.1	9
410	Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. Journal of the American College of Cardiology, 2004, 43, 2000-2008.	2.8	46
411	The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty. Journal of the American College of Cardiology, 2004, 44, 14-19.	2.8	151
412	Arginase pathway in human endothelial cells in pathophysiological conditions. Journal of Molecular and Cellular Cardiology, 2004, 37, 515-523.	1.9	92
413	Co-expression and modulation of neuronal and endothelial nitric oxide synthase in human endothelial cells. Journal of Molecular and Cellular Cardiology, 2004, 37, 939-945.	1.9	75
414	Improvement of cardiac function and β-adrenergic signal transduction by propionyl L-carnitine in congestive heart failure due to myocardial infarction. Coronary Artery Disease, 2004, 15, 65-71.	0.7	18

#	Article	IF	CITATIONS
415	PERTINENTperindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovascular Drugs and Therapy, 2003, 17, 83-91.	2.6	26
416	Skeletal muscle abnormalities in rats with experimentally induced heart hypertrophy and failure. Basic Research in Cardiology, 2003, 98, 114-123.	5.9	11
417	Preliminary observations on the effects of acute infusion of growth hormone on coronary vasculature and on myocardial function and energetics of an isolated and blood-perfused heart. Journal of Endocrinological Investigation, 2003, 26, RC1-RC4.	3.3	4
418	Oxidative stress in cardiovascular disease: myth or fact?. Archives of Biochemistry and Biophysics, 2003, 420, 217-221.	3.0	143
419	Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. Archives of Biochemistry and Biophysics, 2003, 420, 255-261.	3.0	76
420	Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. American Heart Journal, 2003, 146, 854.	2.7	27
421	Short-Term Heart Rate Variability Strongly Predicts Sudden Cardiac Death in Chronic Heart Failure Patients. Circulation, 2003, 107, 565-570.	1.6	770
422	Serum From Patients With Acute Coronary Syndromes Displays a Proapoptotic Effect on Human Endothelial Cells. Circulation, 2003, 107, 264-270.	1.6	66
423	Species-specific modulation of the nitric oxide pathway after acute experimentally induced endotoxemia. Critical Care Medicine, 2003, 31, 1509-1514.	0.9	15
424	Chromogranin A in heart failure. A novel neurohumoral factor and a predictor for mortality. European Heart Journal, 2002, 23, 967-974.	2.2	189
425	Cellular Thiols Redox Status: a Switch for NF-κB Activation During Myocardial Post-ischaemic Reperfusion. Journal of Molecular and Cellular Cardiology, 2002, 34, 997-1005.	1.9	30
426	urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. Journal of the American College of Cardiology, 2002, 40, 155-161.	2.8	74
427	Future strategies of reverse remodeling prevention of hibernation. Journal of Cardiac Failure, 2002, 8, S542-S548.	1.7	1
428	Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) International Journal of Cardiology, 2002, 86, 77-85.	1.7	54
429	Revascularization of hibernating myocardium. Rate of metabolic and functional recovery and occurrence of oxidative stress. European Heart Journal, 2002, 23, 1877-1885.	2.2	11
430	A Sample-Saving Preparation to Extract DNA-Binding Proteins from Cardiac and Vascular Tissues. Laboratory Investigation, 2002, 82, 667-669.	3.7	0
431	Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. Heart Failure Reviews, 2002, 7, 187-203.	3.9	83
432	Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovascular Drugs and Therapy, 2002, 16, 149-160.	2.6	118

#	Article	IF	CITATIONS
433	Apoptosis of Endothelial Cells Precedes Myocyte Cell Apoptosis in Ischemia/Reperfusion Injury. Circulation, 2001, 104, 253-256.	1.6	349
434	Ace-Inhibition with Quinapril Modulates the Nitric Oxide Pathway in Normotensive Rats. Journal of Molecular and Cellular Cardiology, 2001, 33, 395-403.	1.9	39
435	β-Adrenergic receptors and intracellular signalling pathway in stunned and non-ischemic regions of pig myocardium. Basic Research in Cardiology, 2001, 96, 388-394.	5.9	2
436	Neurohormones, cytokines and programmed cell death in heart failure: a new paradigm for the remodeling heart. Cardiovascular Drugs and Therapy, 2001, 15, 529-537.	2.6	5
437	Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril. British Journal of Pharmacology, 2001, 133, 145-153.	5.4	17
438	The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. American Journal of Cardiology, 2001, 87, 1058-1063.	1.6	222
439	The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. American Journal of Cardiology, 2001, 88, 1-20.	1.6	202
440	New insights on myocardial pyridine nucleotides and thiol redox state in ischemia and reperfusion damage. Cardiovascular Research, 2000, 47, 586-594.	3.8	54
441	Sensitivity, specificity, and predictive accuracies of non-invasive tests, singly and in combination, for diagnosis of hibernating myocardium. European Heart Journal, 2000, 21, 1358-1367.	2.2	58
442	Reduction of oxidative stress by carvedilol: role in maintenance of ischaemic myocardium viability. Cardiovascular Research, 2000, 47, 556-566.	3.8	32
443	Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Journal of the American College of Cardiology, 2000, 35, 569-582.	2.8	2,171
444	Chromogranin A and Tumor Necrosis Factor- $\hat{l}\pm$ (TNF) in Chronic Heart Failure. , 2000, 482, 351-359.		50
445	Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor-î±. European Heart Journal, 1999, 20, 1503-1513.	2.2	37
446	Serum From Patients With Severe Heart Failure Downregulates eNOS and Is Proapoptotic. Circulation, 1999, 100, 1983-1991.	1.6	209
447	High-Dose Heparin Impairs Nitric Oxide Pathway and Vasomotion in Rats. Circulation, 1999, 99, 2861-2863.	1.6	14
448	Endothelial Dysfunction in Congestive Heart Failure: Effects of Carvedilol. Heart Failure Reviews, 1999, 4, 53-64.	3.9	3
449	Changes in oxidative stress and cellular redox potential during myocardial storage for transplantation: experimental studies. Journal of Heart and Lung Transplantation, 1999, 18, 478-487.	0.6	19
450	lschemic preconditioning, myocardial stunning, and hibernation: Basic aspects. American Heart Journal, 1999, 138, S61-S68.	2.7	29

#	Article	IF	CITATIONS
451	Cardioprotection: Intermittent Ventricular Fibrillation and Rapid Pacing Can Induce Preconditioning in the Blood-perfused Rat Heart. Journal of Molecular and Cellular Cardiology, 1999, 31, 1961-1973.	1.9	24
452	Role of A2A Receptor in the Modulation of Myocardial Reperfusion Damage. Journal of Cardiovascular Pharmacology, 1999, 33, 883-893.	1.9	47
453	Hibernating myocardium: Its pathophysiology and clinical role. Molecular and Cellular Biochemistry, 1998, 186, 195-199.	3.1	14
454	Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovascular Drugs and Therapy, 1998, 12, 291-299.	2.6	78
455	Metabolic derangement in ischemic heart disease and its therapeutic control. American Journal of Cardiology, 1998, 82, 2K-13K.	1.6	41
456	Metabolic management of ischemic heart disease: introduction. American Journal of Cardiology, 1998, 82, 1K.	1.6	1
457	Tumor necrosis factor in congestive heart failure: A mechanism of disease for the new millennium?. Progress in Cardiovascular Diseases, 1998, 41, 25-30.	3.1	52
458	Skeletal muscle myosin heavy chain expression in rats with monocrotaline-induced cardiac hypertrophy and failure. Relation to blood flow and degree of muscle atrophy. Cardiovascular Research, 1998, 39, 233-241.	3.8	41
459	"Myocardial stunningâ€: Cardiovascular Research, 1998, 38, 549-558.	3.8	33
460	Hibernating myocardium: Its pathophysiology and clinical role. , 1998, , 195-199.		5
461	Effects of Lercanidipine on Fe2+-Induced Mitochondrial Lipid Peroxidation. Journal of Cardiovascular Pharmacology, 1997, 29, S63-S72.	1.9	2
462	Angiotensin converting enzyme inhibitor–calcium antagonist combination. Journal of Hypertension, 1997, 15, S109-S117.	0.5	14
463	The propionyl-l-carnitine hypothesis: An alternative approach to treating heart failure. Journal of Cardiac Failure, 1997, 3, 217-224.	1.7	32
464	Acute Increase of Myocardial Workload, Hemodynamic Instability, and Myocardial Histological Changes Induced by Brain Death in the Cat. Journal of Surgical Research, 1997, 68, 7-15.	1.6	30
465	Reperfusion Injury: Does It Exist and Does It Have Clinical Relevance?. Journal of Thrombosis and Thrombolysis, 1997, 4, 25-34.	2.1	18
466	Pathophysiological Mechanisms of Chronic Reversible Left Ventricular Dysfunction due to Coronary Artery Disease (Hibernating Myocardium). Circulation, 1997, 96, 3205-3214.	1.6	132
467	Aorta and Skeletal Muscle NO Synthase Expression in Experimental Heart Failure. Journal of Molecular and Cellular Cardiology, 1996, 28, 2241-2248.	1.9	78
468	Skeletal Muscle Metabolism in Experimental Heart Failure. Journal of Molecular and Cellular Cardiology, 1996, 28, 2263-2273.	1.9	13

ROBERTO FERRARI

#	Article	IF	CITATIONS
469	Is Stunning an Important Component of Preconditioning?. Journal of Molecular and Cellular Cardiology, 1996, 28, 2323-2331.	1.9	7
470	Metabolic and Functional Consequences of Successive No-flow and Sustained Low-flow Ischaemia; a31P MRS Study in Rat Hearts. Journal of Molecular and Cellular Cardiology, 1996, 28, 2373-2381.	1.9	19
471	Continuous versus intermittent warm blood cardioplegia: Functional and energetics changes. Annals of Thoracic Surgery, 1996, 62, 1172-1179.	1.3	16
472	Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonists. American Journal of Cardiology, 1996, 77, 22D-25D.	1.6	12
473	Effects of felodipine on the ischemic heart: Insight into the mechanism of cytoprotection. Cardiovascular Drugs and Therapy, 1996, 10, 425-437.	2.6	9
474	Relation between energy metabolism, glycolysis, noradrenaline release and duration of ischemia. Molecular and Cellular Biochemistry, 1996, 160-161, 187-194.	3.1	13
475	Metabolic Adaptation During a Sequence of No-Flow and Low-Flow Ischemia. Circulation, 1996, 94, 2587-2596.	1.6	66
476	Calcium antagonists and left ventricular dysfunction. American Journal of Cardiology, 1995, 75, E71-E76.	1.6	10
477	Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure. Circulation, 1995, 92, 1479-1486.	1.6	452
478	Calcium and Calcium Channel Regulation in Cardiac Function. Medical Science Symposia Series, 1995, , 57-64.	0.0	0
479	Echocardiography during infusion of dobutamine for identification of reversible dyfunction in patients with chronic coronary artery disease. Journal of the American College of Cardiology, 1994, 23, 617-626.	2.8	354
480	Effect of Angiotensin Converting Enzyme Inhibition with Quinaprilat on the Ischaemic and Reperfused Myocardium. Journal of Molecular and Cellular Cardiology, 1994, 26, 69-86.	1.9	22
481	Effect of lacidipine on ischaemic and reperfused isolated rabbit hearts. Molecular and Cellular Biochemistry, 1993, 125, 73-86.	3.1	9
482	Plasma levels of atrial natriuretic factor (ANF) and urinary excretion of ANF, arginine vasopressin and catecholamines in children with congenital heart disease: effect of cardiac surgery. European Journal of Cardio-thoracic Surgery, 1993, 7, 533-539.	1.4	16
483	Cardioprotection by nisoldipine: role of timing of administration. European Heart Journal, 1993, 14, 1258-1272.	2.2	43
484	Prolonged propionyl-L-carnitine pre-treatment of rabbit: Biochemical, hemodynamic and electrophysiological effects on myocardium. Journal of Molecular and Cellular Cardiology, 1992, 24, 219-232.	1.9	33
485	Lipid peroxidation during myocardial reperfusion. Molecular and Cellular Biochemistry, 1992, 111, 49-54.	3.1	9
486	Occurrence of oxidative stress during myocardial reperfusion. Molecular and Cellular Biochemistry, 1992, 111, 61-69.	3.1	64

#	Article	IF	CITATIONS
487	Role of timing of administration in the cardioprotective effect of fructose-1,6-bisphosphate. Cardiovascular Drugs and Therapy, 1992, 6, 209-217.	2.6	9
488	Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart. Naunyn-Schmiedeberg's Archives of Pharmacology, 1992, 346, 339-44.	3.0	5
489	Stunning: Damaging or Protective to the Myocardium?. , 1992, , 166-179.		0
490	Oxygen free radicals and myocardial damage: Protective role of thiol-containing agents. American Journal of Medicine, 1991, 91, S95-S105.	1.5	201
491	Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure. Journal of the American College of Cardiology, 1991, 17, 208-217.	2.8	33
492	The influence of right heart catheterisation on pulmonary arterial pressure in chronic heart failure: relationship to neuroendocrinal changes. International Journal of Cardiology, 1991, 33, 365-376.	1.7	5
493	Role of oxygen free radicals in ischemic and reperfused myocardium. American Journal of Clinical Nutrition, 1991, 53, 215S-222S.	4.7	75
494	Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. American Journal of Cardiology, 1991, 67, 732-736.	1.6	73
495	Stunning: Damaging or protective to the myocardium?. Cardiovascular Drugs and Therapy, 1991, 5, 939-945.	2.6	20
496	The occurrence of oxidative stress during reperfusion in experimental animals and men. Cardiovascular Drugs and Therapy, 1991, 5, 277-287.	2.6	43
497	Effects of some L-carnitine derivatives on heart membrane ATPases. Cardiovascular Drugs and Therapy, 1991, 5, 25-30.	2.6	32
498	Time course of human atrial natriuretic factor release during cardiopulmonary bypass in mitral valve and coronary artery diseased patients. European Journal of Cardio-thoracic Surgery, 1991, 5, 205-210.	1.4	11
499	Effects of temperature on myocardial calcium homeostasis and mitochondrial function during ischemia and reperfusion. Journal of Thoracic and Cardiovascular Surgery, 1990, 99, 919-928.	0.8	35
500	Occurrence of oxidative stress during reperfusion of the human heart Circulation, 1990, 81, 201-211.	1.6	280
501	Enalapril as initial and sole treatment in severe chronic heart failure with sodium retention. International Journal of Cardiology, 1990, 28, 341-346.	1.7	24
502	Prolonged protective effect of the calcium antagonist anipamil on the ischemic reperfused rabbit myocardium: Comparison with verapamil. Cardiovascular Drugs and Therapy, 1989, 3, 403-412.	2.6	19
503	Effect of D-600 on ischemic and reperfused rabbit myocardium: relation with timing and modality of administration. Basic Research in Cardiology, 1989, 84, 606-622.	5.9	31
504	Protective effect of propionyl-L-carnitine against ischaemia and reperfusion-damage. Molecular and Cellular Biochemistry, 1989, 88, 161-8.	3.1	36

#	Article	IF	CITATIONS
505	Hemodynamic, hormonal, and renal effects of atrial natriuretic peptide in untreated congestive cardiac failure. American Heart Journal, 1989, 118, 500-505.	2.7	20
506	Effects of iloprost (ZK 36374) on glutathione status during ischaemia and reperfusion of rabbit isolated hearts. British Journal of Pharmacology, 1989, 98, 678-684.	5.4	32
507	Noradrenaline, atrial natriuretic peptide, bombesin and neurotensin in myocardium and blood of rats in congestive cardiac failure. Cardiovascular Research, 1989, 23, 674-682.	3.8	59
508	Effect of lipid peroxidation on heart mitochondria oxygen consuming and calcium transporting capacities. Molecular and Cellular Biochemistry, 1988, 81, 131-5.	3.1	25
509	Protective effect of a prostacyclin-mimetic on the ischaemic-reperfused rabbit myocardium. Journal of Molecular and Cellular Cardiology, 1988, 20, 1095-1106.	1.9	26
510	Long-Lasting Protective Effect of Anipamil, a New Calcium Entry Blocker, against Myocardial Ischemia and Reperfusion Damage. Annals of the New York Academy of Sciences, 1988, 522, 522-524.	3.8	1
511	Effects of verapamil and nifedipine on rate of left ventricular relaxation in coronary arterial disease patients. International Journal of Cardiology, 1987, 14, 333-341.	1.7	17
512	Effects of calcium entry blockers not connected with calcium channels inhibition. General Pharmacology, 1987, 18, 431-436.	0.7	15
513	Myocardial recovery during post-ischaemic reperfusion: Effects of nifedipine, calcium and magnesium. Journal of Molecular and Cellular Cardiology, 1986, 18, 487-498.	1.9	146
514	Changes in the cardiac glutathione status after ischemia and reperfusion. Experientia, 1985, 41, 42-43.	1.2	115
515	Oxygen-mediated myocardial damage during ischameia and reperfusion: Role of the cellular defences against oxygen toxicity. Journal of Molecular and Cellular Cardiology, 1985, 17, 937-945.	1.9	370
516	Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium. American Journal of Cardiology, 1980, 46, 242-248.	1.6	480
517	Lactate production after left ventricular angiography in coronary artery disease. American Heart Journal, 1978, 96, 835-836.	2.7	2
518	Prolonged protective effect of propranolol on hypoxic heart muscle. American Journal of Cardiology, 1978, 42, 217-225.	1.6	36